Company profile: Spyre Therapeutics
1.1 - Company Overview
Company description
- Provider of antibody therapies for inflammatory bowel disease (IBD), including SPY001, a monoclonal antibody targeting α4β7 integrin designed for potency, selectivity, and human compatibility, and SPY002, a TL1A-binding monoclonal antibody with high potency and selectivity. Conducts pre-clinical and planned clinical studies of rational combinations (SPY120, SPY130, SPY230) and precision immunology for genetic/biomarker-based patient selection.
Products and services
- SPY002: High-potency monoclonal antibody that binds TL1A for IBD treatment, engineered for selectivity and intended to treat inflammatory bowel disease through TL1A targeting
- SPY001: Human-compatible monoclonal antibody targeting α4β7 integrin for IBD, created for potency and selectivity to address inflammatory bowel disease via precise α4β7 engagement
- Rational Combinations: Preclinical-to-clinical antibody combinations (SPY120, SPY130, SPY230) for IBD, evaluated in pre-clinical and planned clinical studies for inflammatory bowel disease treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spyre Therapeutics
Functional Gut Diagnostics
HQ: United Kingdom
Website
- Description: Provider of cutting-edge technology, test kits, and analysis for gut health, enabling healthcare providers to gather critical clinical data to aid diagnosis and treatment decisions, while improving performance, delivery, analytical power, and diagnostic test assistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Functional Gut Diagnostics company profile →
Inventiva
HQ: France
Website
- Description: Provider of oral small molecule therapies in development for fibrosis, lysosomal storage disorders and oncology. Pipeline includes lanifibranor (Phase III for NASH) and odiparcil (Phase IIa for MPS VI), the PanNASH research initiative, partnerships with Sino Biopharm and Hepalys Pharma, and a 240,000-compound library supporting discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inventiva company profile →
HalioDx
HQ: France
Website
- Description: Provider of diagnostic tests in oncology utilizing the immune contexture of cancers; designs and develops cancer diagnostics based on immune contexture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HalioDx company profile →
Techlab
HQ: United States
Website
- Description: Provider of intestinal diagnostics products, including patented QUIK CHEK rapid tests delivering extremely accurate results in 30 minutes; founded in 1989, headquartered in Blacksburg, VA, with a state-of-the-art manufacturing facility in Radford, VA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Techlab company profile →
Prometheus Laboratories
HQ: United States
Website
- Description: Provider of precision gastroenterology diagnostics and tools, including: PredictrPK precision-guided dosing tests for infliximab and adalimumab using serology markers, patient variables, current dosing and machine-learning to optimize biologic therapy for IBD; Anser therapeutic drug monitoring measuring drug levels and antibodies; Monitr disease monitoring for IBD; and CDPATH prognostic tool predicting Crohn's complications risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prometheus Laboratories company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spyre Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spyre Therapeutics
2.2 - Growth funds investing in similar companies to Spyre Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spyre Therapeutics
4.2 - Public trading comparable groups for Spyre Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →